[Urgent need for new antimalarias (author's transl)].
D000962:Antimalarials / Q000627:therapeutic use*; D001682:Biological Availability; D002738:Chloroquine / Q000627:therapeutic use; D004338:Drug Combinations / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D006801:Humans; D007167:Immunotherapy; D015767:Mefloquine; D010880:Piperidines / Q000627:therapeutic use; D011739:Pyrimethamine / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D013413:Sulfadoxine / Q000627:therapeutic use; D014944:World Health Organization
D000962:Antimalarials; D004338:Drug Combinations; D010880:Piperidines; D011804:Quinolines; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D002738:Chloroquine; D015767:Mefloquine; D011739:Pyrimethamine
Dringlichkeit der Entwicklung neurer Antimalariamittel.